Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agentsXuanhong Jin, Liangkun You, Cheng Cheng et al.|Frontiers in Pharmacology|2024Cited by 3